Format

Send to

Choose Destination
Curr Opin Oncol. 2007 Jan;19(1):55-60.

Ba/F3 cells and their use in kinase drug discovery.

Author information

1
Kinase Platform and Department of Lead Discovery, Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, USA. mwarmuth@gnf.org

Abstract

PURPOSE OF REVIEW:

Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics. The discovery of a large number of cancer-associated mutations in the kinome, and the progress in developing specific small-molecule kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems.

RECENT FINDINGS:

Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-molecule kinase inhibitors to block kinase activity. Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compound profiling. Further, several published approaches show promise in predicting resistance to small-molecule kinase inhibitors elicited by point mutations interfering with inhibitor binding.

SUMMARY:

Ba/F3 cells are an increasingly popular tool in kinase drug discovery. The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compound libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clinical resistance will greatly facilitate developments in this field.

PMID:
17133113
DOI:
10.1097/CCO.0b013e328011a25f
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center